Key Stats for GE Healthcare Stock
- Past-Week Performance: -4.7%
- 52-Week Range: $57.7 to $89.8
- Current Price: $72.3
What Happened?
GE HealthCare Technologies (GEHC), a maker of diagnostic imaging systems, MRI scanners, and contrast agents used in hospitals worldwide, absorbed a $0.43-per-share tariff headwind in 2025, still grew adjusted EPS 2.2% to $4.59, and now guides 2026 EPS to $4.95–$5.15 with tariff pressure guided lower, all while the stock trades at $72.34, roughly 19% below its 52-week high of $89.77.
GE HealthCare reported Q4 2025 adjusted EPS of $1.44, beating the $1.40 consensus, on revenue of $5.70 billion that topped the $5.61 billion estimate, as its Pharmaceutical Diagnostics segment, which sells contrast media and radiopharmaceuticals used to enhance medical scans, posted 12.7% organic growth and its Imaging unit, the company’s largest segment at $2.55 billion in Q4 revenue, grew 6.6%.
Underpinning the 2026 growth case, GEHC exited 2025 with a record backlog of $21.8 billion, up $2 billion year-over-year, supported by a book-to-bill ratio of 1.07x on a trailing 12-month basis, a demand signal that peers Siemens Healthineers and Philips have not matched at this scale heading into the same product cycle.
The pending acquisition of Intelerad, a cloud-based medical imaging archiving and workflow software platform, is expected to close in the first half of 2026, adding approximately $270 million in first-year revenue growing low double digits and an adjusted EBITDA margin above 30%, which accelerates GEHC’s strategy of building higher-margin, recurring software revenue alongside its capital equipment business.
CFO Jay Saccaro stated on the Q4 2025 earnings call that “in the initial roll-up, the tariff bill was like $1 billion, and we very quickly mitigated that to $0.5 billion,” then tied that execution directly to the Heartbeat lean business system GEHC deployed mid-2025, which also drove a 25% average monthly improvement in past-due backlog in the second half of the year.
Nine major product launches, including the Photonova Spectra photon-counting CT scanner (FDA review underway, approval expected in 2026) and the Flyrcado cardiac PET agent, which hit 220 weekly doses on January 23 and carries a $500 million-plus revenue target by end-2028, position GEHC to add 1 to 2 percentage points of innovation-driven growth on top of the guided 3% to 4% organic base beginning in 2027.
Wall Street’s Take on GEHC Stock
GEHC’s Q4 beat and record $21.8 billion backlog confirm that tariff neutralization and a nine-product innovation cycle are converging at exactly the moment the stock, at $72.34, prices in neither.
The TIKR model estimates revenue reaching $21.6 billion in 2026 and $22.6 billion in 2027, supported by the $2 billion year-over-year backlog build and management’s confirmed 3% to 4% organic growth guide, with EBITDA margin expanding from 18.1% in 2025 to 18.5% in 2026 and 19.0% in 2027 as tariff drag falls below the prior year’s $245 million hit and higher-margin new products enter the revenue mix.
Fourteen of 20 analysts covering GEHC hold a buy or outperform rating, with a mean price target of $93.05 and a median of $95.00, implying 28.6% upside from the March 17 close of $72.34, a consensus anchored on Flyrcado dose ramp acceleration and Photonova Spectra FDA clearance expected in 2026.
The analyst price target range spans $75.00 on the low end to $110.00 on the high end: the bear case assumes China remains a multi-year drag and Omnipaque market share erodes faster than GEHC’s 20-SKU portfolio can absorb Amneal’s generic entry, while the bull case reflects full Photonova and total body PET revenue contribution beginning in 2027.
What Does the Valuation Model Say?
The TIKR mid-case target of $98.77 implies a 4.4% revenue CAGR through 2030 and net income margins expanding from 10.2% in 2025 to 11.6% in the mid case, a trajectory directly justified by the Heartbeat-driven 25% past-due backlog improvement and the Intelerad acquisition adding $270 million in first-year recurring software revenue above 30% adjusted EBITDA margin.
The market is pricing GEHC at roughly 14.3x 2026E normalized EPS of $5.06, a distressed multiple, despite tariff headwinds guided lower and nine major product launches entering the order book.
Record backlog of $21.8 billion plus 1.07x trailing book-to-bill directly supports the TIKR mid-case $98.77 target, with Photonova Spectra orders and Flyrcado dose ramp as the two variables that determine whether 2027 EPS of $5.57 proves conservative.
CFO Saccaro’s confirmation that tariffs are now “neutral to positive” to 2026 financial performance, versus a $0.43-per-share drag in 2025, is the single most underappreciated management signal in the current setup.
China, guided down and representing approximately 10% of total sales, is the one variable that breaks the model if commercial recovery stalls; a sustained decline would pressure the 3% to 4% organic revenue growth assumption and push EBITDA margin expansion below the guided 50 to 80 basis points.
Photonova Spectra FDA clearance, expected in 2026, is the single event to watch; orders taken post-approval convert to revenue primarily in 2027, and the weekly Flyrcado dose count each quarter is the real-time signal of whether the $500 million-plus end-2028 target is tracking.
Should You Invest in GE HealthCare Technologies Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up GEHC stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track GE HealthCare Technologies Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze GEHC stock on TIKR for Free →
